Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABI1
REST API REST API
Homo sapiens
ABI1 is differentially expressed in 328 experiments: 125 organism parts: liver, amygdala, ... (123 more);, 229 disease states: normal, glioblastoma, ... (227 more);, 106 cell types 382 cell lines 39 compound treatments and 81 other conditions.
Synonyms ABI-1, SSH3BP1, E3B1
Orthologs abi1a (Danio rerio)   ABI1 (Gallus gallus)   ENSCING00000012655 (Ciona intestinalis)   Q0VCW2_BOVIN (Bos taurus)   Abi1 (Rattus norvegicus)   Abi1 (Mus musculus)   Abi (Drosophila melanogaster)   abi1 (Xenopus laevis)   ABI1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein tyrosine kinase activator activity, cytosol, endoplasmic reticulum, protein binding, cellular process, cytoskeleton, cytoplasm, cellular component movement, intracellular, negative regulation of cell proliferation, actin polymerization or depolymerization, peptidyl-tyrosine phosphorylation, cell leading edge, somitogenesis, transmembrane receptor protein tyrosine kinase signaling pathway, synaptosome, cell junction, soluble fraction, filopodium, nucleus, lamellipodium, growth cone, synapse, cytoskeletal protein binding, positive regulation of protein tyrosine kinase activity
InterPro Term T_SNARE_dom, SH3_domain, SH3_2, p67phox, Abl-interactor_HHR_dom
UniProt Accession Q8IZP0, Q5T2R9, Q59G41, A6NFN2, B4DQ58, F5H1G9, F8WA56, F8WA55
Search EB-eye ENSG00000136754
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
primary culture
2
E-GEOD-1657, E-GEOD-2450
MDA468
2
E-MEXP-440, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC1937
2
E-MTAB-37, E-MTAB-62
376 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (47 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
testis - germ cell
2
E-AFMX-5, E-TABM-145
monocyte
1
2
E-GEOD-22373, E-GEOD-11755, E-MEXP-583
primary fibroblast
1
E-MEXP-66
intrathymic T progenitor cell
1
E-GEOD-1460
activated natural killer cell
1
E-TABM-702
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-12254, ... (62 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
lung adenocarcinoma
2
E-MTAB-62, E-MEXP-231
neuroblastoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-995, E-GEOD-96
223 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (28 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
CNOT7+CNOT8
1
1
E-MEXP-2218
17beta-estradiol
4
1
E-GEOD-2292
TGF
1
E-GEOD-15205
nocodazole
1
E-GEOD-6431
33 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
28
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, E-GEOD-21589, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-TABM-147, E-GEOD-1751, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-TABM-601, E-MEXP-1838, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-1956, E-MEXP-2069, ... (40 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-1082, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.45 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM